Simultaneous integrated dose reduction intensity-modulated radiotherapy improves survival in patients with locally advanced non-small cell lung cancer by reducing cardiac irradiation exposure

被引：0
作者：
Xu, Chang [1 ]
Wu, Jiehan [1 ]
Liu, Bingxin [2 ]
Meng, Hanheng [3 ]
Zhao, Lujun [1 ]
Wang, Ping [1 ]
Sun, Jifeng [4 ]
Wang, Jun [1 ]
Liu, Ningbo [1 ,5 ]
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc,Key Laboratory of Cancer P, Tianjins Clin Res Ctr Canc,Dept Radiat Oncol, Tianjin, Peoples R China
[2] Lehigh Univ, P C Rossin Coll Engn & Appl Sci, 27 Mem Dr West, Bethlehem, PA 18015 USA
[3] Shanxi Datong Univ, Peoples Hosp Datong Canc Hosp 2, Affiliated Canc Hosp, Dept Radiat Oncol, Datong, Shanxi, Peoples R China
[4] Konggang Branch Tianjin Canc Hosp, Dept Radiat Oncol, Dong Fifth Rd, Tianjin, Peoples R China
[5] Hetian Dist Peoples Hosp, Hetian 848000, Xinjiang, Peoples R China
来源：
DISCOVER ONCOLOGY | 2025年 / 16卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Non-small-cell lung cancer (NSCLC); Intensity modulated radiotherapy (IMRT); Simultaneous integrity dose reduction; Radiation oncology; SEVERE LYMPHOPENIA; RADIATION-THERAPY; STAGE; CONCURRENT; DISEASE; CHEMORADIATION; CARBOPLATIN; PACLITAXEL; SAFETY; BOOST;
D O I：
10.1007/s12672-025-02046-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The study aimed to evaluate the safety and efficacy of simultaneous integrated dose reduction intensity-modulated radiotherapy (SIR-IMRT) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). In the SIR-IMRT conhort, the prescribed irradiation dose was 60 Gray (Gy) for the planning gross tumor volume (PGTV) and 54 Gy for the planning target volume (PTV), while in the conventional intensity-modulated radiotherapy (C-IMRT) cohort, it was 60 Gy for both PGTV and PTV. The SIR-IMRT group demonstrated better overall survival (OS) than the C-IMRT group, with a median OS of 37.7 versus 31.2 months. The SIR-IMRT group also experienced lower cardiac and esophagusal doses, along with a lower incidence of acute radiation esophagitis and >= grade 3 radiation pneumonitis. HeartV20 (the volume of the heart receiving at least 20 Gy) was the only independent risk factor associated with survival. SIR-IMRT significantly reduced cardiac irradiation exposure, improving patient survival and offering a new therapeutic direction for future studies.
引用
收藏
页数：13
相关论文
共 29 条
  • [1] Bradley J.D., Paulus R., Komaki R., Masters G., Blumenschein G., Schild S., Bogart J., Hu C., Forster K., Magliocco A., Kavadi V., Garces Y.I., Narayan S., Iyengar P., Robinson C., Wynn R.B., Koprowski C., Meng J., Beitler J., Gaur R., Curran W., Choy H., Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two
  • [2] Chen V.W., Ruiz B.A., Hsieh M.-C., Wu X.-C., Ries L.A.G., Lewis D.R., Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system, Cancer, 120, 23, pp. 3781-3792, (2014)
  • [3] Contreras J.A., Lin A.J., Weiner A., Speirs C., Samson P., Mullen D., Campian J., Bradley J., Roach M., Robinson C., Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer, Radiother Oncol, 128, pp. 498-504, (2018)
  • [4] Curran W.J., Paulus R., Langer C.J., Komaki R., Lee J.S., Hauser S., Movsas B., Wasserman T., Rosenthal S.A., Gore E., Machtay M., Sause W., Cox J.D., Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410, J Natl Cancer Inst, 103, pp. 1452-1460, (2011)
  • [5] Darby S.C., Ewertz M., McGale P., Bennet A.M., Blom-Goldman U., Bronnum D., Correa C., Cutter D., Gagliardi G., Gigante B., Jensen M.-B., Nisbet A., Peto R., Rahimi K., Taylor C., Hall P., Risk of ischemic heart disease in women after radiotherapy for breast cancer, N Engl J Med, 368, pp. 987-998, (2013)
  • [6] Dillman R.O., Herndon J., Seagren S.L., Eaton W.L., Green M.R., Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial, J Natl Cancer Inst, 88, pp. 1210-1215, (1996)
  • [7] Ettinger D.S., Wood D.E., Aisner D.L., Akerley W., Bauman J.R., Bharat A., Bruno D.S., Chang J.Y., Chirieac L.R., D'Amico T.A., Dilling T.J., Dowell J., Gettinger S., Gubens M.A., Hegde A., Hennon M., Lackner R.P., Lanuti M., Leal T.A., Lin J., Loo B.W., Lovly C.M., Martins R.G., Massarelli E., Morgensztern D., Ng T., Otterson G.A., Patel S.P., Riely G.J., Schild S.E., Shapiro T.A., Singh A.P., Stevenson J., Tam A., Yanagawa J., Yang S.C., Gregory K.M., Hughes M., NCCN guidelines insights: non-
  • [8] Friedes C., Chakrabarti T., Olson S., Prichett L., Brahmer J.R., Forde P.M., Voong R.K., Marrone K.A., Lam V.K., Hann C.L., Broderick S.R., Battafarano R.J., Ha J.S., Bush E.L., Yang S.C., Hales R.K., Feliciano J.L., Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy, Lung Cancer, 154, pp. 36-43, (2021)
  • [9] Hayashi Y., Iijima H., Isohashi F., Tsujii Y., Fujinaga T., Nagai K., Yoshii S., Sakatani A., Hiyama S., Shinzaki S., Makino T., Yamasaki M., Ogawa K., Doki Y., Takehara T., The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study, BMC Cancer, 19, (2019)
  • [10] Herbst R.S., Morgensztern D., Boshoff C., The biology and management of non-small cell lung cancer, Nature, 553, pp. 446-454, (2018)
123